An observational study in Hypertension, Pulmonary, Hypertension;Pulmonary;Primary and Chronic Thromboembolic Pulmonary Hypertension, sponsored by University of Giessen. Enrolling by invitation at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-19.
Sponsored by University of Giessen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hypertension, Pulmonary by University of Giessen — 5 open to participants now, 5 under way, none of them phase 3. Hypertension, Pulmonary · University of Giessen.
Among the 13 studies in Hypertension, Pulmonary by University of Giessen, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2018, is one of 11 observational ones, and was the 6th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →5 of the 13 studies in Hypertension, Pulmonary by University of Giessen are open now, in 1 country. Recruiting first, the newest first:
University of Giessen · Sites in Germany
Ages 18+ · Healthy volunteers
University of Giessen · Sites in Germany
Ages 18+
University of Giessen · Sites in Germany
Healthy volunteers
University of Giessen · Sites in Germany
By country, each count listing its studies:
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2018.
This study's planned enrollment of 500 is above the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.
Median enrollment 57 across the 2 interventional studies, 500 across the 11 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Giessen is the lead sponsor of 95 studies on the registry; 22 are open to participants now.
1 of the studies in Hypertension, Pulmonary by University of Giessen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06409624University of GiessenAssociation Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Hypertension, Pulmonary by University of Giessen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Measurement of the endtidal carbon dioxide by capnography to exclude or to ensure the diagnosis pulmonary hypertension. The aim of the study is to obtain an endtidal carbon dioxide cut-off value for the diagnostic algorithm for pulmonary hypertension as an easily measurable and cheap diagnostic tool in patients with suspicion of pulmonary hypertension.
The disease pulmonary hypertension is due to a remodeling of the lung vessels which results in a change of the exhaled air. This change is measurable with a so called capnograph. The investigators want to measure the breath from patients with and without pulmonary hypertension to detect a cut-off value for the diagnosis pulmonary hypertension.
Patients which have the probably diagnosis pulmonary hypertension and are older than 18 years are investigated. This patients will get an right heart catheterization and a measurement from their exhaled air.
Patients of a tertiary referral center retro- and prospective part of the study.
Afterwards in a next prospective study part patients in ambulant setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age > 18 years, suspicion of pulmonary hypertension, planned or accomplished right heart catheterization
Exclusion Criteria:
none
At Patients with suspicion of pulmonary hypertension, which get a right heart catheterization, in the context of the study the exhaled air, precious the endtidal carbon dioxide (CO2), before or after the right heart catheterization will be measured through capnography.
Diagnostic Test: Capnography
Measuring of the exhaled air, especially endtidal co2, through capnography.
Measurement PetCO2
Measurement PetCO2 by capnography at rest after or before a right heart catheterization, comparison of the parameter between patients with and without
Time frame: At baseline
Establishing a cut-off
Establishing a cut-off for the non-invasive diagnosing of pulmonary hypertension, which differs between patients with and without pulmonary hypertension and save patients without the disease before a dispensable invasive right heart catheterization
Time frame: At baseline
Plan to share: No
Started May 2018 (actual). Primary completion is estimated for Jan 2030, 139 months after the start.
Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 139 months is above that.
Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Giessen